Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

678 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.
Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, Vetlova E, Harting I, Debus J, Hartmann C, Kunz C, Platten M, Bendszus M, Combs SE. Wick W, et al. Clin Cancer Res. 2014 Dec 15;20(24):6304-13. doi: 10.1158/1078-0432.CCR-14-0951-T. Epub 2014 Oct 22. Clin Cancer Res. 2014. PMID: 25338498 Clinical Trial.
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. Uhl M, et al. Among authors: wick w. Cancer Res. 2004 Nov 1;64(21):7954-61. doi: 10.1158/0008-5472.CAN-04-1013. Cancer Res. 2004. PMID: 15520202
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Tan TC, Sommer C, Bamberg M, Reifenberger G, Weller M. Herrlinger U, et al. Among authors: wick w. J Clin Oncol. 2006 Sep 20;24(27):4412-7. doi: 10.1200/JCO.2006.06.9104. J Clin Oncol. 2006. PMID: 16983109 Clinical Trial.
A novel tool to analyze MRI recurrence patterns in glioblastoma.
Wick W, Stupp R, Beule AC, Bromberg J, Wick A, Ernemann U, Platten M, Marosi C, Mason WP, van den Bent M, Weller M, Rorden C, Karnath HO; European Organisation for Research and Treatment of Cancer and the National Cancer Institute of Canada Clinical Trials Group. Wick W, et al. Among authors: wick a. Neuro Oncol. 2008 Dec;10(6):1019-24. doi: 10.1215/15228517-2008-058. Epub 2008 Jul 31. Neuro Oncol. 2008. PMID: 18676355 Free PMC article.
Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R.
Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, Tolosa E, Hoberg M, Anderl J, Aicher WK, Weller M, Wick W, Platten M. Opitz CA, et al. Among authors: wick w. Stem Cells. 2009 Apr;27(4):909-19. doi: 10.1002/stem.7. Stem Cells. 2009. PMID: 19353519
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A. Hartmann C, et al. Among authors: wick w. Acta Neuropathol. 2009 Oct;118(4):469-74. doi: 10.1007/s00401-009-0561-9. Epub 2009 Jun 25. Acta Neuropathol. 2009. PMID: 19554337 Free article.
678 results